CoreAge Rx vs Bliv
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Bliv head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
Bliv
FDA warning letter, February 2026 — issued to Bliv Wellness LLC dba Bliv. See the FDA's warning letter database.
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 63 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.
That doesn't make Bliv a bad call — it's best for readers who can obtain the full selected-plan quote and distinguish subscription, clinical evaluation and pharmacy charges. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Compare | CoreAge Rx | Bliv |
|---|---|---|
| Brief Score | 94/100 (A) | 63/100 (C) |
| Semaglutide | From $79/mo Annual offer: 12 months paid upfront, from $948. Main site: from $99/mo; confirm the selected offer. Full price detailsFrom $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo | As low as $116/month Based on plan structure and eligibility; full upfront charge, dose and supply unconfirmed. Generic $58/month promotion is not a complete semaglutide quote. Medication charged after approval; refund cutoff is prescription transmission. Subscription cancellation does not cancel a pending prescription. Full price detailsCompounded semaglutide offered; complete current selected-plan quote unknown; public page lists as low as $116/month based on plan structure and eligibility, alongside a generic $58/month promotion |
| Tirzepatide | From $129/mo Annual offer: 12 months paid upfront, from $1,548. Main site: from $149/mo; confirm the selected offer. Full price detailsFrom $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo | As low as $199/month Based on plan structure and eligibility; selected total and supply unconfirmed. Financing installment is not the medication price. Evaluation fee becomes final after evaluation and offered treatment; paid subscription fees ordinarily are not prorated. Medication has its own cutoff. Full price detailsCompounded tirzepatide offered; complete current selected-plan quote unknown; public page lists as low as $199/month based on plan structure and eligibility, alongside a generic $58/month promotion |
| Coverage | US only; restrictions by state, confirmed at intake | U.S. care requires a clinician licensed for the patient’s physical location; exact treatment-specific coverage requires confirmation |
| Brand-name access | Not confirmed | Current branded GLP-1 prescribing availability was not established on the reviewed pages. |
| Oral / sublingual | Injection only | Unconfirmed |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.
Bliv: As-low-as figures depend on plan and eligibility; full selected payment unconfirmed. Current terms separate subscription, evaluation and medication charges; pharmacy transmission ends ordinary medication refunds.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.